Serum lipoprotein(a) level and its clinical significance in patients with systemic lupus erythematosus

Sari R., Polat M. F., Taysi S., Bakan E., Capoglu I.

CLINICAL RHEUMATOLOGY, cilt.21, sa.6, ss.520-524, 2002 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 6
  • Basım Tarihi: 2002
  • Doi Numarası: 10.1007/s100670200127
  • Dergi Adı: CLINICAL RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.520-524
  • Anahtar Kelimeler: atherosclerosis, lipoprotein(a), systemic lupus erythematosus, LOW-DENSITY-LIPOPROTEIN, APOLIPOPROTEIN(A) DEPOSITION, ANTIPHOSPHOLIPID ANTIBODIES, NEPHROTIC SYNDROME, CORONARY-ARTERIES, ATHEROSCLEROSIS, DISEASE, QUANTIFICATION, ATHEROGENESIS, ASSOCIATION
  • Yozgat Bozok Üniversitesi Adresli: Evet

Özet

Systemic lupus erythematosus (SLE) is a classic autoimmune disease characterised by the production of autoreactive T cells and autoantibodies that may affect every organ system. It has long been established that there is a close association between cholesterol-rich lipoproteins (such as low-density lipoprotein-cholesterol) and cardiovascular disease in patients with SLE. In this study, we evaluated total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, VLD-cholesterol, apolipoprotein A-1, apolipoprotein B, and cholesterol-rich serum lipoprotein(a) [Lp(a)], which is accepted to be an independent risk factor for cardiovascular disease and for atherosclerosis, in 24 patients (mean age +/- SD 31.4 +/- 9.7 years, range 16-47, 22 F) with active SLE. Twenty-six healthy age- and sex-matched (mean age +/- SD 29.7 +/- 11.3 years, range 18-49 years, 22 F) subjects were included as a control group. In patients with SLE Lp(a) levels, total cholesterol, triglycerides and VLDL-cholesterol were found to be higher and HDL-cholesterol, apolipoprotein A-1 to be lower than those of controls. In conclusion, beacuse serum Lp(a) levels are significantly higher (P < 0.01) in patients with SLE, these patients have a risk of developing cardiovascular disease and atherosclerosis. Patients with SLE should be followed up with this in mind.